Mini Review ARTICLE
Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading
- 1Centre for Integrated Preclinical Drug Development, The University of Queensland, Brisbane, QLD, Australia
- 2Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
- 3Centre for Advanced Imaging, The University of Queensland, Brisbane, QLD, Australia
- 4ARC Centre of Excellence in Convergent BioNano Science and Technology, Brisbane, QLD, Australia
- 5School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
Poly(lactic-co-glycolic acid) (PLGA) is the most widely used biomaterial for microencapsulation and prolonged delivery of therapeutic drugs, proteins and antigens. PLGA has excellent biodegradability and biocompatibility and is generally recognized as safe by international regulatory agencies including the United States Food and Drug Administration and the European Medicines Agency. The physicochemical properties of PLGA may be varied systematically by changing the ratio of lactic acid to glycolic acid. This in turn alters the release rate of microencapsulated therapeutic molecules from PLGA microparticle formulations. The obstacles hindering more widespread use of PLGA for producing sustained-release formulations for clinical use include low drug loading, particularly of hydrophilic small molecules, high initial burst release and/or poor formulation stability. In this review, we address strategies aimed at overcoming these challenges. These include use of low-temperature double-emulsion methods to increase drug-loading by producing PLGA particles with a small volume for the inner water phase and a suitable pH of the external phase. Newer strategies for producing PLGA particles with high drug loading and the desired sustained-release profiles include fabrication of multi-layered microparticles, nanoparticles-in-microparticles, use of hydrogel templates, as well as coaxial electrospray, microfluidics, and supercritical carbon dioxide methods. Another recent strategy with promise for producing particles with well-controlled and reproducible sustained-release profiles involves complexation of PLGA with additives such as polyethylene glycol, poly(ortho esters), chitosan, alginate, caffeic acid, hyaluronic acid, and silicon dioxide.
Drug delivery systems with high efficiency and tuneable release characteristics continue to be sought. This is despite recent advances in the field of nanobiotechnology that have produced a range of new materials for improving control over drug delivery rates (Hillery et al., 2005). The strategies used to produce these sustained-release dosage forms involve drug loading of biodegradable polymeric microspheres and have the potential to provide a more facile route to adjust release rates (Kapoor et al., 2015).
Poly(lactic-co-glycolic acid) (PLGA), is a widely used biodegradable material use for encapsulation of a broad range of therapeutic agents including hydrophilic and hydrophobic small molecule drugs, DNA, proteins, and the like (Zheng, 2009; Malavia et al., 2015), due to its excellent biocompatibility (Barrow, 2004; Kapoor et al., 2015). Complete release of encapsulated molecules is achieved via degradation and erosion of the polymer matrix (Anderson and Shive, 1997, 2012; Fredenberg et al., 2011). Importantly, PLGA is generally recognized as safe by international regulatory agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in pharmaceutical products administered to humans via conventional oral and parenteral routes (Yun-Seok et al., 2010) as well as suspension formulations for implantation without surgical procedures (Freiberg and Zhu, 2004).
However, factors limiting more widespread use of PLGA in pharmaceutical products include relatively low drug loading efficiency, difficulties in controlling encapsulated drug release rates and/or formulation instability (Varde and Pack, 2004; Freitas et al., 2005; Yun-Seok et al., 2010; Ansari et al., 2012; Danhier et al., 2012; Reinhold and Schwendeman, 2013). In the following sections, we review strategies and new technologies with promise for addressing these issues.
Challenges in Improving Drug Loading of Microparticles with Acceptable Control Over Release Rate Profiles
Physicochemical Properties of the Incorporated Drug(s)
Achieving the desired loading of low molecular weight (Mr), hydrophilic molecules in polymeric particles is more difficult than for hydrophobic small molecules, despite the large number of micro-encapsulation methods described in peer-reviewed publications and patents (Ito et al., 2011; Ansari et al., 2012). Manipulation of the physicochemical properties is often the most effective means for optimizing drug loading into PLGA microspheres (Curley et al., 1996; Govender et al., 1999). For example, small molecules that are hydrophilic in their salt form can be converted to the corresponding free acid or free base forms that are more hydrophobic, subsequently leading to higher drug loading (Han et al., 2015). The physicochemical properties of the incorporated drug(s) also significantly affect release rate profiles (Hillery et al., 2005).
For PLGA microparticles, release of the encapsulated drug occurs via diffusion and/or homogeneous bulk erosion of the biopolymer (Siegel et al., 2006; Kamaly et al., 2016) with the diffusion rate dependent upon drug diffusivity and partition coefficient (Hillery et al., 2005). These parameters are influenced by the physicochemical properties of the drug, such as molecular size, hydrophilicity, and charge (Hillery et al., 2005). A relatively high content of a water-soluble drug facilitates water penetration into particles and formation of a highly porous polymer network upon drug leaching (Feng et al., 2015). By contrast, hydrophobic drugs can hinder water diffusion into microparticulate systems and reduce the rate of polymer degradation (Klose et al., 2008). This is illustrated by observations that for six drugs with diverse chemical structures, viz. thiothixene, haloperidol, hydrochlorothiozide, corticosterone, ibuprofen and aspirin, there were significant between-molecule differences in release rate from PLGA (50:50) pellets, despite their similar drug loading at 20% by weight (Siegel et al., 2006). Hence, the design of biodegradable polymeric carriers with high drug loading must take into consideration the effects of the encapsulated drug itself on the mechanisms underpinning biopolymer degradation that influence release rate (Siegel et al., 2006).
Key factors in the design of microparticle drug delivery systems include microsphere size and morphology (Langer et al., 1986; Shah et al., 1992; Mahboubian et al., 2010) as these parameters potentially affect encapsulation efficiency (EE), product injectability, in vivo biodistribution, and encapsulated drug release rate (Nijsen et al., 2002; Barrow, 2004), efficacy and side-effect profiles (Liggins et al., 2004). Typically, optimal release profiles are achieved by using microspheres with diameters in the range, 10–200 μm (Anderson and Shive, 1997). For particle diameters < 10 μm, there is a risk that microspheres will be phagocytosed by immune cells (Dawes et al., 2009). On the other hand, microspheres >200 μm may cause an immune response and inflammation (Dawes et al., 2009).
For large diameter particles, the small surface area per unit volume leads to a reduced rate of water permeation and matrix degradation relative to smaller particles and so the maximum possible rate of encapsulated drug release is reduced (Dawes et al., 2009). For drugs microencapsulated in larger microparticles, duration of action is potentially longer due to higher total drug loading and a longer particle degradation time (Klose et al., 2006). Hence, a good understanding of the relationship between biopolymer composition, microparticle morphology and size is essential for tailored production of particulate materials with pre-determined drug release profiles (Cai et al., 2009). However, based upon the diversity of encapsulated drug release profiles produced by PLGA microspheres of varying sizes to date (Table 1), release rates do not necessarily conform to predicted behavior and it is only possible to quantitatively predict the effect of microparticle size on drug release kinetics for certain well-defined formulations (Siepmann et al., 2004).
Table 1. Influence of particle size, polymer physicochemical properties as well as PLGA composition on drug loading and release profiles..
Biodegradation Mechanisms of PLGA-Microparticles
The two main mechanisms that drive drug release from PLGA microspheres are diffusion and degradation/erosion (Kamaly et al., 2016). For PLGA (50:50) particles, drug release occurs in two phases. In the first phase, there is a rapid decrease in molecular weight (Mr) but little mass loss whereas in the second phase, the opposite occurs. This indicates that PLGA particle degradation involves heterogeneous mechanisms and that drug release is underpinned primarily by diffusion rather than polymer degradation (Engineer et al., 2010).
PLGA is a typical bulk-eroding biopolymer such that water permeates readily into the polymer matrix forming pores so that degradation takes place throughout the microspheres (Varde and Pack, 2004). Comparison of encapsulated drug release profiles from surface eroding biopolymers such as poly(ortho esters) (POE) and polyanhydrides with bulk-eroding biopolymers such as PLGA, is lacking. Hence, future research addressing this knowledge gap is needed to better inform design of microparticle formulations with the desired release profiles (Engineer et al., 2010) that may potentially include formulations comprising mixed bulk and surface-eroding biopolymers (Feng et al., 2015).
Physicochemical Properties of the Biopolymer
For drugs encapsulated in PLGA microparticles, the desired release rates can be achieved by adjusting the ratio of lactic acid to glycolic acid and by altering the physicochemical properties [e.g., Mr, end-group (ester or carboxylic) functionality] that influence microparticle morphology (Table 1; Mao et al., 2007; Cai et al., 2009; Gasparini et al., 2010; Nafissi-Varcheh et al., 2011). The physical properties of PLGA particles are also dependent upon the drug delivery device size, exposure to water (surface shape), as well as storage temperature and humidity (Table 1) (Houchin and Topp, 2009). These properties not only affect the ability of the biopolymer to be formulated but also influence its degradation rate (Table 1; Makadia and Siegel, 2011). Another factor that contributes to encapsulated drug release from PLGA microspheres is the concentration of polymer in the organic solvent during formulation (Wasana et al., 2009).
Choice of Surfactant
During microparticle formulation using conventional solvent evaporation methods, an emulsifier is required to ensure droplet stability until the polymer concentration in the organic solvent is sufficiently high to maintain particle conformation (Chemmunique, 1980; Hwisa et al., 2013). The most widely used emulsifier in the preparation of PLGA micro/nanoparticles is poly (vinyl alcohol) (PVA) (Wang et al., 2015). It is worth noting that D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS; FDA-approved as a water-soluble vitamin E nutritional supplement) markedly improved drug loading at a concentration an order of magnitude lower (0.3 mg/ml) than analogous systems that used PVA (5 mg/ml) (Feng et al., 2007).
Methods for Producing Microparticles for Sustained-Release Formulations
Drugs, including many small molecules, that are soluble in the polymer solution, can be encapsulated by simply co-dissolving with the polymer for the most commonly used methods (Table 2).
Table 2. Methods for producing PLGA based microparticles for sustained-release formulations: Advantages and Disadvantages.
For the water-soluble salts of small molecule drugs, encapsulation efficiency can be improved by their conversion to a hydrophobic form, such as by complexation with ionic surfactants (Cohen et al., 1991) or to the corresponding free acid or free base form (Han et al., 2015). Alternative approaches include suspension of solid (e.g., lyophilized) particulates in the polymer solution; or use of a water-in-oil-in-water (w/o/w) solvent evaporation (double-emulsion) method. When using a w/o/w method, relatively higher drug loading and reproducible sustain-release profiles can be achieved by formulations that have a smaller volume for the inner water phase (Wasana et al., 2009; Chaudhari et al., 2010), a low preparation temperature (Yang et al., 2000; Fu et al., 2005; Chaudhari et al., 2010; Ito et al., 2011) and a suitable pH of the external phase (Bodmeier and Mcginity, 1988; Govender et al., 1999; Leo et al., 2004).
Recent Advances with Promise for Improving PLGA-Based Drug Delivery Systems
Hydrogel templates enable high drug loading (~50%) and high incorporation efficiencies (~100%) to be achieved and are amenable to small molecules and biologics (Tables 1, 2) (Malavia et al., 2015). Any water insoluble material can be used as the microparticle matrix to produce the desired drug release profiles, and microparticles are recovered from the readily soluble hydrogel templates. The technology allows for precise control of the size and shape of template wells in every dimension so that microparticles with a narrow size distribution can be produced (Lu et al., 2014; Malavia et al., 2015). These attributes enable sustained-release microparticles to be produced for injection using narrow bore needles into sensitive spaces such as the eye, with nearly zero-order drug release for over 3 months with virtually no initial burst release (Malavia et al., 2015). However, more research is needed to better understand the effect of microparticle size and shape on encapsulated drug release kinetics and in vivo performance for a broad range of molecules with widely differing physicochemical properties.
Coaxial electrospray (CES) produces double-layered microparticles using an electric field applied to both the outer (PLGA carrier) and the inner (drug loaded) solutions sprayed simultaneously through two separate feeding channels of a coaxial needle into the one nozzle (Yuan et al., 2015). At a certain voltage threshold, a conical shape (e.g., “Taylor cone”) forms and the jets of liquids (both inner and outer flows) are broken into double-layered microparticles (Yuan et al., 2015). In the CES process, a compound Taylor cone with a core-shell structure is formed on top of the spray nozzle, and the outer polymeric solution encapsulates the inner liquid (Yuan et al., 2015). The bulk liquid is broken into small charged droplets by coulombic repulsion (Yuan et al., 2015). Using this technique, parameters such as orientation of the jets, material flow rates, and rate of solvent extraction can be controlled to create uniform and well-centered double-walled microspheres exhibiting a controllable shell thickness (Makadia and Siegel, 2011). The CES process enables effective encapsulation of proteins, drugs, and contrast agents with high efficiency, minimal loss of biological viability, and excellent control of core-shell architecture (Tables 1, 2) (Zamani et al., 2014; Yuan et al., 2015).
Microfluidic devices use electrostatic forces to control the size and shape of particles for enhanced tuning of drug release characteristics (Zhang et al., 2013). Microfluidic systems have been employed for fabrication of complex drug carriers with precise size and composition leading to a predictable and tuneable release profile (Tables 1, 2) (Leon et al., 2015; Riahi et al., 2015). Two continuous and immiscible streams (i.e., oil and water) are infused via two separate inlets (Xu et al., 2009). Monodisperse droplets are generated at the junction where the two streams meet due to the high shear stress. The droplet sizes are in the range 20–100 μm (Xu et al., 2009) and 100–300 nm (Xie et al., 2012). In contrast to the classical double emulsion methods, multiple components are easily generated by a single-step emulsification in the microfluidic device (Xie et al., 2012). By introducing the second stream, droplets may be re-encapsulated which is useful for preparing core-shell structures (Nie et al., 2006).
A novel and versatile microfluidic approach for fabrication of PLGA/PCL Janus and microcapsule particles involves changing the organic solvent of the dispersed phase from dimethyl carbonate to dichloromethane (Li et al., 2015). The shell on the microcapsule particle surface is comprised of PLGA only, and the core is comprised of PCL in which tiny PLGA beads are embedded (Li et al., 2015). Interestingly, the Janus and microcapsule particles exhibited distinct degradation behaviors, implying their potential for differential effects on drug delivery and release profiles (Li et al., 2015).
Supercritical CO2 (scCO2) provides a “green” alternative to traditional microparticle formulation techniques as it avoids use of toxic organic solvents or elevated temperatures (Tables 1, 2) (Budisa and Schulze-Makuch, 2014). Owing to the very short encapsulation process (5–10 min) at a relatively low temperature and modest pressure, and absence of organic solvents, the activity of bioactive molecules including proteins is maintained (Howdle et al., 2001; Koushik and Kompella, 2004; Della Porta et al., 2013). Because the complete process is anhydrous, it can be used to produce sustained-release formulations of multiple hydrophilic molecules (Thote and Gupta, 2005).
New variations to the use of scCO2 technology take advantage of other properties of CO2 such as its capacity to extract active pharmaceutical ingredients (APIs) from natural compounds or to form polymers (Champeau et al., 2015). New protocols under development hold promise for fabricating drug-eluting implants using a scCO2 impregnation process (Champeau et al., 2015).
Drug/protein/peptide loaded microspheres can be prepared by spraying a solid-in-oil dispersion or water-in-oil emulsion in a stream of heated air without significant losses (Makadia and Siegel, 2011). The type of drug (hydrophobic or hydrophilic) for encapsulation informs the choice and nature of the solvent to be used, whereas the temperature of the solvent evaporation step and feed rate affect microsphere morphology (Tables 1, 2) (Makadia and Siegel, 2011). Various spray drying techniques have been reported and are reviewed elsewhere (Wan and Yang, 2016).
“Self-healing” is a phenomenon whereby polymers with damaged structures (e.g., pores, cracks, and dents), undergo spontaneous rearrangement of the polymer chains to produce healing (repair) (Syrett et al., 2010). This is important because pore closure in PLGA microparticles at physiological temperature impedes the pore-diffusion pathway and greatly reduces initial burst release of a micro-encapsulated peptide (Wang et al., 2002). Similarly, porous PLGA microspheres loaded with recombinant human growth hormone (rhGH) prepared by the solvent evaporation technique and using the surfactant pluronic F127 as porogen, underwent pore closure at the polymer surface following solvent exposure (Kim et al., 2006). These “healed” non-porous microspheres exhibited sustained drug release profiles over an extended period (Kim et al., 2006). The post-healing approach can be used to overcome shear-induced microparticle degradation, solvent-associated erosion of delicate core materials, or unexpected payload release during emulsification (Tables 1, 2) (Na et al., 2012). Strategies for “healing” pores in the microparticle surface include solvent swelling, or infrared irradiation which is potentially an even milder approach for inducing self-healing (Na et al., 2012).
Complexing PLGA with Additives
As noted in an earlier section of this review, the chemical composition of PLGA-particulate drug delivery systems greatly influences their physicochemical properties, and this in turn governs the biodistribution and pharmacokinetics of the encapsulated drug (Zhang et al., 2013). Hence, complexation of PLGA with suitable additives (Table 1) including poly(ethylene glycol) (PEG), POE, chitosan and/or alginate, caffeic acid, hyaluronic acid, TPGS, and SiO2 (Shi et al., 2003; Graves et al., 2004; Zheng and Liang, 2010; Lim et al., 2013; Navaei et al., 2014; Abulateefeh and Alkilany, 2015; Sanna et al., 2015; Selmin et al., 2015; Wang et al., 2015), may lead to higher drug loading and the desired sustained release profile (Shi et al., 2003; Graves et al., 2004; Zheng and Liang, 2010; Lim et al., 2013; Navaei et al., 2014; Abulateefeh and Alkilany, 2015; Sanna et al., 2015; Selmin et al., 2015).
Other strategies with promise for improving controlled-release drug delivery systems include double walled/layered PLGA (Navaei et al., 2014) and nanoparticles-in-microparticles (Lee et al., 2013). Additionally, polymer-brush PLGA-based drug delivery systems appear promising due to the versatility and controllability of the method for controlling particle shape (Huang et al., 2014).
In the past decade, considerable progress has been made on addressing the issues of (i) low drug loading, (ii) particle instability, and (iii) adequate control of drug release profiles for PLGA-based microparticle drug delivery systems. Strategies for increasing drug loading in PLGA-microspheres include modification of the classical solvent evaporation methods, preparation of multi-layered microparticles, and development of novel methods for microparticle fabrication including hydrogel templates, coaxial electrospray, microfluidics, and scCO2. Additionally, methods involving complexation of PLGA with additives such as PEG, POE, chitosan and/or alginate, caffeic acid, hyaluronic acid and SiO2, appear promising. Nevertheless, there is a great need for innovation in development of time-efficient methods for controlling the factors that influence drug loading and release profiles as a means to inform the design of next-generation controlled-release drug delivery systems (Draheim et al., 2015).
All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.
FH is supported by a postdoctoral fellowship funded by a National Health and Medical Research Council (NHMRC) grant, APP1107723.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abulateefeh, S. R., and Alkilany, A. M. (2015). Synthesis and characterization of PLGA shell microcapsules containing aqueous cores prepared by internal phase separation. AAPS PharmSciTech. 16. doi: 10.1208/s12249-015-0413-y. [Epub ahead of print].
Acharya, G., Shin, C. S., Mcdermott, M., Mishra, H., Park, H., Kwon, I. C., et al. (2010a). The hydrogel template method for fabrication of homogeneous nano/microparticles. J. Control Release 141, 314–319. doi: 10.1016/j.jconrel.2009.09.032
Acharya, G., Shin, C. S., Vedantham, K., Mcdermott, M., Rish, T., Hansen, K., et al. (2010b). A study of drug release from homogeneous PLGA microstructures. J. Control Release 146, 201–206. doi: 10.1016/j.jconrel.2010.03.024
Baxendale, A., van Hooff, P., Durrant, L. G., Spendlove, I., Howdle, S. M., Woods, H. M., et al. (2011). Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology. Int. J. Pharm. 413, 147–154. doi: 10.1016/j.ijpharm.2011.04.053
Cai, C., Mao, S., Germershaus, O., Schaper, A., Rytting, E., Chen, D., et al. (2009). Influence of morphology and drug distribution on the release process of FITC-dextran-loaded microspheres prepared with different types of PLGA. J. Microencapsul. 26, 334–345. doi: 10.1080/02652040802354707
Champeau, M., Thomassin, J. M., Tassaing, T., and Jérôme, C. (2015). Drug loading of polymer implants by supercritical CO2 assisted impregnation: a review. J. Control Release 209, 248–259. doi: 10.1016/j.jconrel.2015.05.002
Chaudhari, K. R., Shah, N., Patel, H., and Murthy, R. (2010). Preparation of porous PLGA microspheres with thermoreversible gel to modulate drug release profile of water-soluble drug: bleomycin sulphate. J. Microencapsul. 27, 303–313. doi: 10.3109/02652040903191818
Cho, D. I. D., and Yoo, H. J. (2015). Microfabrication methods for biodegradable polymeric carriers for drug delivery system applications: a review. J. Microelectromech. Sys. 24, 10–18. doi: 10.1109/JMEMS.2014.2368071
Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L. H., and Langer, R. (1991). Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8, 713–720. doi: 10.1023/A:1015841715384
Curley, J., Castillo, J., Hotz, J., Uezono, M., Hernandez, S., Lim, J.-O., et al. (1996). Prolonged regional nerve blockade: Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology 84, 1401–1410.
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., and Préat, V. (2012). PLGA-based nanoparticles: an overview of biomedical applications. J. Control Release 161, 505–522. doi: 10.1016/j.jconrel.2012.01.043
Dawes, G. J. S., Fratila-Apachitei, L. E., Mulia, K., Apachitei, I., Witkamp, G. J., and Duszczyk, J. (2009). Size effect of PLGA spheres on drug loading efficiency and release profiles. J. Mater. Sci. Mater. M. 20, 1089–1094. doi: 10.1007/s10856-008-3666-0
Della Porta, G., Falco, N., Giordano, E., and Reverchon, E. (2013). PLGA microspheres by supercritical emulsion extraction: a study on insulin release in myoblast culture. J. Biomater. Sci. Polym. Ed. 24, 1831–1847. doi: 10.1080/09205063.2013.807457
Dhanda, D. S., Tyagi, P., Mirvish, S. S., and Kompella, U. B. (2013). Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J. Control Release 168, 239–250. doi: 10.1016/j.jconrel.2013.03.027
Draheim, C., De Crécy, F., Hansen, S., Collnot, E. M., and Lehr, C. M. (2015). A design of experiment study of nanoprecipitation and nano spray drying as processes to prepare PLGA nano- and microparticles with defined sizes and size distributions. Pharm. Res. 32, 2609–2624. doi: 10.1007/s11095-015-1647-9
Dunne, M., Corrigan, O. I., and Ramtoola, Z. (2000). Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21, 1659–1668. doi: 10.1016/S0142-9612(00)00040-5
Falco, N., Reverchon, E., and Della Porta, G. (2012). Continuous supercritical emulsions extraction: packed tower characterization and application to poly(lactic-co-glycolic Acid) plus insulin microspheres production. Ind. Eng. Chem. Res. 51, 8616–8623. doi: 10.1021/ie300482n
Feng, S., Lu, F., Wang, Y., and Suo, J. (2015). Comparison of the degradation and release behaviors of poly(lactide-co-glycolide)-methoxypoly(ethylene glycol) microspheres prepared with single- and double-emulsion evaporation methods. J. Appl. Polym. Sci. 132:41943. doi: 10.1002/app.41943
Feng, S.-S., Zeng, W., Teng Lim, Y., Zhao, L., Yin Win, K., Oakley, R., et al. (2007). Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine (Lond.) 2, 333–344. doi: 10.2217/174358184.108.40.2063
Fredenberg, S., Wahlgren, M., Reslow, M., and Axelsson, A. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-A review. Int. J. Pharmaceut. 415, 34–52. doi: 10.1016/j.ijpharm.2011.05.049
Freitas, S., Merkle, H. P., and Gander, B. (2005). Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control Release 102, 313–332. doi: 10.1016/j.jconrel.2004.10.015
Fu, X., Ping, Q., and Gao, Y. (2005). Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J. Microencapsul. 22, 705–714. doi: 10.1080/02652040500162196
Gasparini, G., Holdich, R. G., and Kosvintsev, S. R. (2010). PLGA particle production for water-soluble drug encapsulation: degradation and release behaviour. Colloids Surf. B Biointerfaces 75, 557–564. doi: 10.1016/j.colsurfb.2009.09.035
Govender, T., Stolnik, S., Garnett, M. C., Illum, L., and Davis, S. S. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control Release 57, 171–185. doi: 10.1016/S0168-3659(98)00116-3
Graves, R. A., Pamujula, S., Moiseyev, R., Freeman, T., Bostanian, L. A., and Mandal, T. K. (2004). Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules. Int. J. Pharmaceut. 270, 251–262. doi: 10.1016/j.ijpharm.2003.10.019
Han, F. Y., Thurecht, K. J., Lam, A. L., Whittaker, A. K., and Smith, M. T. (2015). Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain. J. Pharm. Sci. 104, 2334–2344. doi: 10.1002/jps.24497
Howdle, S. M., Watson, M. S., Whitaker, M. J., Popov, V. K., Davies, M. C., Mandel, F. S., et al. (2001). Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. Chem. Commun. 2001, 109–110. doi: 10.1039/b008188o
Huang, Y., Morinaga, T., Tai, Y., Tsujii, Y., and Ohno, K. (2014). Immobilization of semisoft colloidal crystals formed by polymer-brush-afforded hybrid particles. Langmuir 30, 7304–7312. doi: 10.1021/la5011488
Hung, L. H., Teh, S. Y., Jester, J., and Lee, A. P. (2010). PLGA micro/nanosphere synthesis by droplet microfluidic solvent evaporation and extraction approaches. Lab Chip 10, 1820–1825. doi: 10.1039/c002866e
Hwisa, N. T., Katakam, P., Chandu, B. R., and Adiki, S. K. (2013). Solvent evaporation techniques as promising advancement in microencapsulation. VRI Biol. Med. Chem. 1, 8–22. doi: 10.14259/bmc.v1i1.29
Ito, F., Fujimori, H., Kawakami, H., Kanamura, K., and Makino, K. (2011). Technique to encapsulate a low molecular weight hydrophilic drug in biodegradable polymer particles in a liquid-liquid system. Colloids Surf. A 384, 368–373. doi: 10.1016/j.colsurfa.2011.04.017
Jordan, F., Naylor, A., Kelly, C. A., Howdle, S. M., Lewis, A., and Illum, L. (2010). Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control Release 141, 153–160. doi: 10.1016/j.jconrel.2009.09.013
Kamaly, N., Yameen, B., Wu, J., and Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116, 2602–2663. doi: 10.1021/acs.chemrev.5b00346
Kim, H. K., Chung, H. J., and Park, T. G. (2006). Biodegradable polymeric microspheres with “open/closed” pores for sustained release of human growth hormone. J. Control Release 112, 167–174. doi: 10.1016/j.jconrel.2006.02.004
Klose, D., Siepmann, F., Elkhamz, K., and Siepmann, J. (2008). PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int. J. Pharm. 354, 95–103. doi: 10.1016/j.ijpharm.2007.10.030
Klose, D., Siepmann, F., Elkharraz, K., Krenzlin, S., and Siepmann, J. (2006). How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314, 198–206. doi: 10.1016/j.ijpharm.2005.07.031
Koushik, K., and Kompella, U. B. (2004). Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharmaceut. Res. 21, 524–535. doi: 10.1023/B:PHAM.0000019308.25479.A4
Lee, Y. S., Johnson, P. J., Robbins, P. T., and Bridson, R. H. (2013). Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study. Eur. J. Pharm. Biopharm. 83, 168–173. doi: 10.1016/j.ejpb.2012.10.016
Leo, E., Brina, B., Forni, F., and Vandelli, M. A. (2004). In vitro evaluation of PLA nanoparticles containing a lipophilic rug in water-soluble or insoluble form. Int. J. Pharmaceut. 278, 133–141. doi: 10.1016/j.ijpharm.2004.03.002
Leon, R.A.L., Somasundar, A., Badruddoza, A. Z. M., and Khan, S. A. (2015). Microfluidic fabrication of multi-drug-loaded polymeric microparticles for topical glaucoma therapy. Part. Part. Syst. Char. 32, 567–572. doi: 10.1002/ppsc.201400229
Li, W. X., Dong, H., Tang, G. N., Ma, T., and Cao, X. D. (2015). Controllable microfluidic fabrication of Janus and microcapsule particles for drug delivery applications. RSC Adv. 5, 23181–23188. doi: 10.1039/C4RA17153E
Liggins, R. T., Cruz, T., Min, W., Liang, L., Hunter, W. L., and Burt, H. M. (2004). Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: biocompatibility and efficacy determinations in rabbits. Inflamm. Res. 53, 363–372. doi: 10.1007/s00011-004-1273-1
Lim, M. P. A., Lee, W. L., Widjaja, E., and Loo, S. C. J. (2013). One-step fabrication of core-shell structured alginate-PLGA/PLLA microparticles as a novel drug delivery system for water soluble drugs. Biomater. Sci. 1, 486–493. doi: 10.1039/c3bm00175j
Mahboubian, A., Hashemein, S. K., Moghadam, S., Atyabi, F., and Dinarvand, R. (2010). Preparation and in-vitro evaluation of controlled release PLGA microparticles containing triptoreline. Iran. J. Pharm. Res. 9, 369–378.
Malavia, N., Reddy, L., Szinai, I., Betty, N., Pi, J., Kanagaraj, J., et al. (2015). Biodegradable sustained-release drug delivery systems fabricated using a dissolvable hydrogel template technology for the treatment of ocular indications. IOVS 56, 1296.
Mao, S., Xu, J., Cai, C., Germershaus, O., Schaper, A., and Kissel, T. (2007). Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int. J. Pharm. 334, 137–148. doi: 10.1016/j.ijpharm.2006.10.036
Nafissi-Varcheh, N., Luginbuehl, V., Aboofazeli, R., and Merkle, H. P. (2011). Preparing poly (lactic-co-glycolic acid) (PLGA) microspheres containing lysozyme-zinc precipitate using a modified double emulsion method. Iran. J. Pharm. Res. 10, 203–209.
Nan, K., Ma, F., Hou, H., Freeman, W. R., Sailor, M. J., and Cheng, L. (2014). Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin. Acta Biomater 10, 3505–3512. doi: 10.1016/j.actbio.2014.04.024
Navaei, A., Rasoolian, M., Momeni, A., Emami, S., and Rafienia, M. (2014). Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study. Drug Dev. Ind. Pharm. 40, 701–710. doi: 10.3109/03639045.2013.777734
Nie, Z., Li, W., Seo, M., Xu, S., and Kumacheva, E. (2006). Janus and ternary particles generated by microfluidic synthesis: design, synthesis, and self-assembly. J. Am. Chem. Soc. 128, 9408–9412. doi: 10.1021/ja060882n
Nijsen, J. F. W., Van Het Schip, A. D., Hennink, W. E., Rook, D. W., Van Rijk, P. P., and De Klerk, J. M. H. (2002). Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumours. Curr. Med. Chem. 9, 73–82. doi: 10.2174/0929867023371454
Park, K. M., Sung, H., Choi, S. J., Choi, Y. J., and Chang, P.-S. (2014). Double-layered microparticles with enzyme-triggered release for the targeted delivery of water-soluble bioactive compounds to small intestine. Food Chem. 161, 53–59. doi: 10.1016/j.foodchem.2014.03.125
Reinhold, S. E., and Schwendeman, S. P. (2013). Effect of polymer porosity on aqueous self-healing encapsulation of proteins in PLGA microspheres. Macromol. Biosci. 13, 1700–1710. doi: 10.1002/mabi.201300323
Riahi, R., Tamayol, A., Shaegh, S. A. M., Ghaemmaghami, A. M., Dokmeci, M. R., et al. (2015). Microfluidics for advanced drug delivery systems. Curr. Opin. Chem. Eng. 7, 101–112. doi: 10.1016/j.coche.2014.12.001
Sanna, V., Roggio, A. M., Pala, N., Marceddu, S., Lubinu, G., Mariani, A., et al. (2015). Effect of chitosan concentration on PLGA microcapsules for controlled release and stability of resveratrol. Int. J. Biol. Macromol. 72, 531–536. doi: 10.1016/j.ijbiomac.2014.08.053
Selmin, F., Puoci, F., Parisi, O. I., Franzé, S., Musazzi, U. M., and Cilurzo, F. (2015). Caffeic Acid-PLGA conjugate to design protein drug delivery systems stable to irradiation. J. Funct. Biomater. 6, 1–13. doi: 10.3390/jfb6010001
Shah, S. S., Cha, Y., and Pitt, C. G. (1992). Poly(glycolic acid-co-dl-lactic acid) - diffusion or degradation controlled drug delivery. J. Control Release 18, 261–270. doi: 10.1016/0168-3659(92)90171-M
Shi, M., Yang, Y. Y., Chaw, C. S., Goh, S. H., Moochhala, S. M., Ng, S., et al. (2003). Double walled POE/PLGA microspheres: encapsulation of water-soluble and water-insoluble proteins and their release properties. J. Control Release 89, 167–177. doi: 10.1016/S0168-3659(02)00493-5
Siegel, S. J., Kahn, J. B., Metzger, K., Winey, K. I., Werner, K., and Dan, N. (2006). Effect of drug type on the degradation rate of PLGA matrices. Eur. J. Pharm. Biopharm. 64, 287–293. doi: 10.1016/j.ejpb.2006.06.009
Siepmann, J., Faisant, N., Akiki, J., Richard, J., and Benoit, J. P. (2004). Effect of the size of biodegradable microparticles on drug release: experiment and theory. J. Control Release 96, 123–134. doi: 10.1016/j.jconrel.2004.01.011
Sosnik, A., and Seremeta, K. P. (2015). Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv. Colloid Interface Sci. 223, 40–54. doi: 10.1016/j.cis.2015.05.003
Thote, A. J., and Gupta, R. B. (2005). Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine 1, 85–90. doi: 10.1016/j.nano.2004.12.001
Viry, L., Moulton, S. E., Romeo, T., Suhr, C., Mawad, D., Cook, M., et al. (2012). Emulsion-coaxial electrospinning: designing novel architectures for sustained release of highly soluble low molecular weight drugs. J. Mater. Chem. 22, 11347–11353. doi: 10.1039/c2jm31069d
Wang, B. M., Wang, J., and Schwendeman, S. P. (2002). Characterization of the initial burst release of a model peptide from poly(d,l-lactide-co-glycolide) microspheres. J. Control Release 82, 289–307. doi: 10.1016/S0168-3659(02)00137-2
Wang, H., Agarwal, P., Zhao, S., Xu, R. X., Yu, J., Lu, X., et al. (2015). Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72, 74–89. doi: 10.1016/j.biomaterials.2015.08.048
Xu, Q. B., Hashimoto, M., Dang, T. T., Hoare, T., Kohane, D. S., Whitesides, G. M., et al. (2009). Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow-focusing device for controlled drug delivery. Small 5, 1575–1581. doi: 10.1002/smll.200801855
Yang, Y. Y., Chia, H.-H., and Chung, T.-S. (2000). Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J. Control Release 69, 81–96. doi: 10.1016/S0168-3659(00)00291-1
Yuan, S., Lei, F., Liu, Z., Tong, Q., Si, T., and Xu, R. X. (2015). Coaxial electrospray of curcumin-loaded microparticles for sustained drug release. PLoS ONE 10:e0132609. doi: 10.1371/journal.pone.0132609
Zamani, M., Prabhakaran, M. P., Thian, E. S., and Ramakrishna, S. (2014). Protein encapsulated core-shell structured particles prepared by coaxial electrospraying: investigation on material and processing variables. Int. J. Pharm. 473, 134–143. doi: 10.1016/j.ijpharm.2014.07.006
Keywords: PLGA microparticles, drug delivery system, hydrophilic molecule, biodegradation mechanisms, tuneable release, microfluidics, supercritical carbon dioxide, hydrogel template
Citation: Han FY, Thurecht KJ, Whittaker AK and Smith MT (2016) Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Front. Pharmacol. 7:185. doi: 10.3389/fphar.2016.00185
Received: 06 May 2016; Accepted: 11 June 2016;
Published: 28 June 2016.
Edited by:Aaron Tan, University College London, UK
Reviewed by:Robert Lust, East Carolina University, USA
Hong Zhan, University of Wisconsin-Madison, USA
Copyright © 2016 Han, Thurecht, Whittaker and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maree T. Smith, email@example.com